Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo do TAK-341 no tratamento da atrofia de múltiplos sistemas

31 de agosto de 2026 atualizado por: Takeda

Um estudo randomizado, duplo-cego, controlado por placebo, de fase 2 para avaliar a eficácia, segurança, tolerabilidade, farmacocinética e farmacodinâmica do TAK-341 intravenoso em indivíduos com atrofia multissistêmica

The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS).

The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo, after each infusion some blood samplings will be taken and other assessments completed.

This trial will be conducted in North America, Europe and Asia.

Visão geral do estudo

Status

Concluído

Descrição detalhada

The drug being tested in this study is called TAK-341. The study will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of intravenous (IV) TAK-341 in participants with multiple system atrophy (MSA).

The study will enroll approximately 158 participants. The study comprises a screening period of up to 42 days (6 weeks), a 52-week double-blind treatment period, and a follow-up safety visit. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant, care provider and investigator during the study:

  • TAK-341
  • Placebo

The change from baseline in UMSARS will be measured at Week 52 post-dose.

This multi-center trial will be conducted worldwide. The duration of treatment in this study will be 52 weeks. Participants will make a follow-up visit to the site after approximately 90 days after the last dose of study treatment.

Tipo de estudo

Intervencional

Inscrição (Real)

158

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Berlin, Alemanha, 10117
        • Charite - Universitatsmedizin Berlin
    • Bavaria
      • München, Bavaria, Alemanha, 81377
        • Klinikum Groshadern, LMU
    • Hesse
      • Kassel, Hesse, Alemanha, 34128
        • Paracelsus-Elena-Klinik Kassel
    • Lower Saxony
      • Hanover, Lower Saxony, Alemanha, 30625
        • Medizinische Hochschule Hannover
    • North Rhine-Westphalia
      • Bochum, North Rhine-Westphalia, Alemanha, 44791
        • Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB) - St. Josef-Hospital
      • Bonn, North Rhine-Westphalia, Alemanha, 53127
        • Deutsches Zentrum fur Neurodegenerative Erkrankung
      • Münster, North Rhine-Westphalia, Alemanha, 48149
        • Universitatsklinikum Munster
    • Saxony
      • Dresden, Saxony, Alemanha, 01307
        • Universitatsklinikum Carl Gustav Carus an der TU Dresden
      • Leipzig, Saxony, Alemanha, 04103
        • Universitatsklinikum Leipzig
      • Aarhus N, Dinamarca, 8200
        • Aarhus Universitetshospital
    • Capital
      • København NV, Capital, Dinamarca, 2400
        • Bispebjerg Hospital
      • Barcelona, Espanha, 08035
        • Hospital Universitario Vall d'Hebron
      • Barcelona, Espanha, 08041
        • Hospital de La Santa Creu i Sant Pau
      • Madrid, Espanha, 28034
        • Hospital Universitario Ramon y Cajal
      • Madrid, Espanha, 28006
        • Hospital Universitario de La Princesa
      • Valencia, Espanha, 46026
        • Hospital Universitari i Politecnic La Fe de Valencia
    • Vizcaya
      • Barakaldo, Vizcaya, Espanha, 48903
        • Hospital Universitario Cruces
    • Michigan
      • Farmington Hills, Michigan, Estados Unidos, 48025
        • Quest Research Institute - Alcanza - HyperCore
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905-0001
        • Mayo Clinic
    • New York
      • New York, New York, Estados Unidos, 10016-6402
        • NYU Langone Health
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27705-4410
        • Duke University School of Medicine
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • The Cleveland Clinic Foundation
    • Texas
      • Dallas, Texas, Estados Unidos, 75390-7208
        • University of Texas Southwestern Medical Center
    • Washington
      • Spokane, Washington, Estados Unidos, 99202-1342
        • Inland Northwest Research
    • Bouches-du-Rhone
      • Marseille, Bouches-du-Rhone, França, 13385
        • Hopitaux de La Timone
      • Salerno, Itália, 84131
        • Azienda Ospedaliera Universitaria OO.RR. San Giovanni di Dio Ruggi dAragona
    • Lazio
      • Rome, Lazio, Itália, 00163
        • IRCCS San Raffaele Roma
    • Lombardy
      • Milan, Lombardy, Itália, 20133
        • Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta
      • Milan, Lombardy, Itália, 20122
        • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
      • Rozzano, Lombardy, Itália, 20089
        • Istituto Clinico Humanitas
    • Veneto
      • Padova, Veneto, Itália, 35126
        • Azienda Ospedale Universita Padova
    • Chiba
      • Chuo-ku, Chiba, Japão, 260-8677
        • Chiba University Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Japão, 060-8638
        • Hokkaido University Hospital
    • Kyoto
      • Kyoto, Kyoto, Japão, 606-8507
        • Kyoto University Hospital
    • Tokyo
      • Bunkyo-Ku, Tokyo, Japão, 113-0033
        • The University of Tokyo Hospital
      • Bunkyo-Ku, Tokyo, Japão, 113-8519
        • Medical Hospital of Tokyo Medical and Dental University
      • Kodaira-Shi, Tokyo, Japão, 187-8551
        • National Center of Neurology and Psychiatry
    • Lisbon District
      • Loures, Lisbon District, Portugal, 2674-514
        • Campus Neurologico Senior
    • Porto District
      • Senhora da Hora, Porto District, Portugal, 4464-513
        • Hospital Pedro Hispano
    • Hampshire
      • Southampton, Hampshire, Reino Unido, SO16 6YD
        • Southampton General Hospital
    • Styria
      • Graz, Styria, Áustria, 8036
        • Medizinische Universitat Graz

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

40 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion criteria:

Diagnostic:

  1. The participant has a diagnosis of possible or probable MSA using the modified Gilman et al, 2008 diagnostic criteria.
  2. The participant's onset of first MSA symptoms occurred ≤4 years before screening, as assessed by the investigator.
  3. Evidence of MSA specific symptoms and deficits as measured by the UMSARS scale.

Exclusion criteria:

Medical History:

1. The participant has any contraindication to study procedures.

Diagnostic Assessments:

  1. Presence of confounding diagnosis and/or conditions that could affect participant's safety during the study per investigator judgement.
  2. The participant's participation in a previous study of a disease-modifying therapy (with proven receipt of active treatment) will compromise the interpretability of the data from the present study, per consultation with medical monitor or designee.

Other:

1. The participant has participated in another study investigating active or passive immunization against α-synuclein (αSYN) for progressive disease (PD) or MSA, or has had immunoglobulin G therapy, within 6 months before screening.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: Placebo

Participants received TAK-341 matching placebo intravenous (IV) infusions, once every 4 weeks (Q4W) for 52 weeks.

TAK-341-matching placebo IV infusion

Experimental: TAK-341

Participants received TAK-341, IV Q4W for 52 weeks. An early set of participants initially received 2400 milligrams (mg) to determine pharmacokinetic (PK) parameters. Following the early participants, a dose of 2000 mg was given until the data from the PK participants became available. All participants then received 2400 mg until the end of treatment at 52 weeks.

TAK-341 IV infusion

Outros nomes:
  • MEDI1341

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52
Prazo: Baseline, Week 52

UMSARS Part I (historical review) is a 12-item scale that was adapted from the Unified Parkinson's Disease Rating Scale (UPDRS) and is used to assess activities related to motor disability and autonomic dysfunction. In this study, the UMSARS was modified to exclude the sexual function item. Thus, total 11 items were assessed. Each item was initially scored on a scale from 0 (normal) to 4 (severe); ratings of normal (0) and mild (1) were then combined and recorded as 0, making minimum score 0 and maximum score 3. The investigator rated the average functional situation for the past 2 weeks according to findings from the participant and caregiver interview and indicated the score that best fit with the participant's status. The total score is a sum of scores from all domains and range from 0 to 33. Higher scores indicate worse impairment.

Baseline, Week 52

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of Participants With Anti-Drug Antibodies
Prazo: Up to Week 61
Up to Week 61
Change From Baseline in 11-item UMSARS at Week 52
Prazo: Baseline, Week 52

The 11- item UMSARS includes 11 items from Part I and II to assess both motor and autonomic disability. UMSARS Part I (historical review) is used to assess activities related to motor disability and autonomic dysfunction. UMSARS Part II (motor examination) is used to measure the functional impairment and specific parkinsonian or cerebellar features. Each item was scored on a scale from 0 (normal) to 4 (severe); total score ranges from 0 to 44, higher scores indicated worse impairment.

Baseline, Week 52
Change From Baseline in the UMSARS Total Score (UMSARS Part I + Part II) at Week 52
Prazo: Baseline, Week 52

UMSARS total scale consists of all items from UMSARS Parts I and II. UMSARS Part I (historical review): 12-item scale used to assess activities related to motor disability and autonomic dysfunction. Each item is scored from 0 (normal) to 4 (severe). UMSARS Part II (motor examination): 14-item scale used to measure the functional impairment (for example speech, rapid alternating movements of the hands, finger taps, leg agility) of selected complex movements, and specific parkinsonian (tremor at rest) or cerebellar (ocular motor dysfunction, heel-shin test) features. The worst affected limb was assessed, and each item was scored from 0 (normal) to 4 (severe). UMSARS Part I and Part II total score is the sum of UMSARS Part I and Part II and ranges from 0 to 104. A higher score indicates worse impairment.

Baseline, Week 52
Change From Baseline in UMSARS Part I 11-Item Score at Week 52
Prazo: Baseline, Week 52

UMSARS Part I (historical review) is a 12-item scale that was adapted from the UPDRS. In this study, the UMSARS was modified to exclude the sexual function item. The UMSARS is used to assess activities related to motor disability and autonomic dysfunction. Each item was scored on a scale from 0 (normal) to 4 (severe). UMSARS Part I 11-item total score is the total score of UMSARS Part I, excluding the sexual function item, and without collapse of ratings of scale items. The UMSARS Part I 11-item total score ranges from 0 to 44, and higher scores indicate worse impairment.

Baseline, Week 52
Change From Baseline in UMSARS Part II at Week 52
Prazo: Baseline, Week 52

UMSARS Part II (motor examination): 14-item scale used to measure the functional impairment (e.g., speech, rapid alternating movements of the hands, finger taps, leg agility) of selected complex movements, and specific parkinsonian (tremor at rest) or cerebellar (ocular motor dysfunction, heel-shin test) features. the worst affected limb was assessed, and each item was scored from 0 (normal) to 4 (severe). The UMSARS Part II total score ranges from 0 to 56, and higher scores indicate worse impairment.

Baseline, Week 52
Change From Baseline on Clinical Global Impression-Severity (CGI-S) Score
Prazo: Baseline, Week 24 and Week 52

The CGI-S is used to assess the clinician's impression of the participant's clinical condition. The clinician rates the current severity of the participant's illness on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (most extremely ill). The rating was based on observed and reported symptoms, behaviour, and function and reflected the severity level at the time of the assessment. A higher score indicates worse impairment.

Baseline, Week 24 and Week 52
Change From Baseline in Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA-AUT) Total Score
Prazo: Baseline, Week 24 and Week 52

The SCOPA-AUT is a participant-reported outcome that assesses autonomic function. Autonomic function is a critical symptom domain for MSA. The scale was completed by participants and consisted of 25 items assessing the following domains: gastrointestinal (7 items), urinary (6 items), cardiovascular (3 items), thermoregulatory (4 items), pupillomotor (1 item), and sexual (2 items for men and 2 items for women). The score for each item ranged from 0 (never experiencing the symptom) to 3 (often experiencing the symptom). The total composite score including all domains was reported. The score range was 0 (no symptoms) to 69 (highest burden of symptoms). A higher score indicates worse impairment.

Baseline, Week 24 and Week 52
Overall Survival (OS) at Week 52
Prazo: At Week 52

OS was estimated with Kaplan-Meier survival estimates, along with 95% confidence interval. A cox proportional hazards model was fitted to model the survival probability with treatment as the predictor. The participants with missing value were censored. The probabilities of survival at Week 52 for participants were estimated and reported.

At Week 52
Change From Baseline in Cerebrospinal Fluid (CSF) Free Alpha-Synuclein (αSYN)
Prazo: Baseline, Week 52

α-Synucleinopathies are diseases characterized by abnormal accumulation of aggregated αSYN. In participants with MSA, αSYN is seen to accumulate primarily in oligodendrocytes, forming glial cytoplasmic inclusions. A negative change from Baseline indicates an improvement.

Baseline, Week 52
Maximum Observed Steady State Serum Concentration (Cmax) for TAK-341
Prazo: On Day 57- immediately before end of infusion (EOI) (60 minutes), 6 hours and 24 hours.

Cmax is the maximum observed serum concentration for TAK-341.

On Day 57- immediately before end of infusion (EOI) (60 minutes), 6 hours and 24 hours.
Time to Maximum Steady State Concentration (Tmax) for TAK-341
Prazo: On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.

Tmax is the time of first occurrence of maximum observed concentration for TAK-341.

On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.
Area Under the Serum Concentration Time Curve (AUCτ) at Steady State for TAK-341
Prazo: On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.

AUCτ is the area under the serum concentration-time curve during a dosing interval.

On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.
CSF Concentration of TAK-341
Prazo: On Day 1, Day 85 and Day 365

Lumbar puncture was performed for CSF on Day 1, Day 85 and Day 365, predose.

On Day 1, Day 85 and Day 365
Number of Participants With at Least One Adverse Event (AE)
Prazo: Up to Week 61

An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event that occurs after administration of the first dose of study treatment and up through 90 days after the last dose of study treatment.

Up to Week 61

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Diretor de estudo: Medical Director, Takeda (Note: This product was divested to Alexion/AstraZeneca in 2026)

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

16 de novembro de 2022

Conclusão Primária (Real)

28 de julho de 2025

Conclusão do estudo (Real)

28 de julho de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

1 de setembro de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de setembro de 2022

Primeira postagem (Real)

2 de setembro de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

24 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

31 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Outros números de identificação do estudo

  • TAK-341-2001
  • 2022-000336-28 (Número EudraCT)
  • jRCT2011220029 (Identificador de registro: jRCT)
  • 2023-509876-40-00 (Ctis)
  • 2023 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever